Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by de Boer, R.A
Right arrow Articles by van Veldhuisen, D.J
Right arrow Search for Related Content
PubMed
Right arrow Articles by de Boer, R.A
Right arrow Articles by van Veldhuisen, D.J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Polypharmacy in chronic heart failure: practical issues regarding the use of angiotensin-converting enzyme inhibitors, beta-blockers and other drugs

R.A de Boer and D.J van Veldhuisen*

Department of Cardiology, Thoraxcenter University Hospital Groningen, Groningen, The Netherlands

* Correspondence: Professor Dr Dirk J. van Veldhuisen, Department of Cardiology, Thoraxcenter, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.

Abstract

Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are the cornerstone for treatment of patients with chronic heart failure (CHF), and are usually combined with diuretics, with or without digoxin. With the development of new, additional treatments, the problem of polypharmacy becomes relevant, and strategies to individualize treatment are warranted. This review considers optimal drug treatment in patients with CHF, focusing on the possible problems that can occur when combining drugs. A hierarchy of drugs is suggested, starting from the assumption of a central role for early and widespread use of ACE inhibitors and beta-blockers. A model of drug therapy is proposed that is based on each patient's individual clinical and genetic considerations, which might serve to further optimize treatment.

Key Words: Angiotensin-converting enzyme inhibitors • beta-blockers • genetics • heart failure • pharmacotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.